HOME >> BIOLOGY >> NEWS
Targeted genetics presents promising data from cystic fibrosis clinical trial

Studies suggest that aerosolized tgAAV-CF is safe, well tolerated, and efficiently delivered to the lung

Seattle, WA-June 5, 2000-Targeted Genetics Corporation (Nasdaq: TGEN) presented data from its Phase I clinical trial of an aerosol formulation of tgAAV-CF, the Company's gene therapy product for the treatment of cystic fibrosis (CF). Dr. Thomas C. Reynolds, Vice President, Clinical Affairs at Targeted Genetics, presented the data in an abstract titled "A Phase I Study of Aerosolized Administration of tgAAV-CF to CF patients with Mild Lung Disease" this weekend at the American Society of Gene Therapy Third Annual Meeting in Denver, Colorado.

The Phase I dose-escalation study evaluated the safety and tolerability of tgAAV-CF delivered via nebulizer to 12 patients age 19-41 (median age 29) with mild CF lung disease. All patients in the study had FEV1 levels (a standard measure of lung function) at least 60% of normal. Doses of 1010, 1011, 1012 and 1013 DNAse Resistant Particles (DRP) were evaluated, with each cohort containing three patients. Patients received a single dose of tgAAV-CF and were followed for 90 days post treatment.

"The aerosolized formulation of tgAAV-CF, which we are developing in collaboration with Celltech Group, plc, is well-tolerated in this patient population," said Dr. Reynolds. "Our ability to achieve broad distribution of tgAAV-CF throughout the lungs of these patients validates the aerosol delivery approach we are taking in developing this product. We are on track to initiate a Phase II multi-dose study of aerosolized tgAAV-CF within the next several months. As with the Phase I study presented today, we are working closely with the Cystic Fibrosis Foundation's Therapeutics Development Network (CFF TDN) in designing and conducting the Phase II study. tgAAV-CF is the first gene therapy approach for CF to be selected by the TDN for collaboration and we are proud to be working with the leading physicians
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 ext 229
Noonan/Russo Communications
4-Jun-2000


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... Reno, NV (PRWEB) , ... July 20, 2017 ... ... a real solution to make clinical trial sites and study participants truly unified. ... manage regulatory compliant (FDA 21 CFR Part 11) research studies entirely on mobile ...
(Date:7/18/2017)... ... July 18, 2017 , ... Blood centers traditionally see ... the region. Nationally, summer is a struggle for community blood centers as high schools ... San Antonio Chamber of Commerce is teaming up with the South Texas ...
(Date:7/17/2017)... (PRWEB) , ... July 17, ... ... of technology-enabled clinical trial solutions, today announced safety software company AB Cube ... the eHealth Solutions business segment to advance technology innovation across life sciences ...
(Date:7/17/2017)... ... 17, 2017 , ... DuPont Pioneer today announced the launch ... (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is now available ... biologicals and digital solutions. , “DuPont Pioneer is building on its long history ...
Breaking Biology Technology:
Cached News: